<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03834948</url>
  </required_header>
  <id_info>
    <org_study_id>AO-176-101</org_study_id>
    <nct_id>NCT03834948</nct_id>
  </id_info>
  <brief_title>AO-176 in Multiple Solid Tumor Malignancies</brief_title>
  <official_title>A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arch Oncology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arch Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, Phase 1/2 multi-center, open-label, dose escalation and expansion
      study of AO-176 which will evaluate the safety, tolerability, pharmacokinetics (PK),
      pharmacodynamics, and clinical effects of AO-176 in patients with advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first-in-human, Phase 1/2 multicenter, open-label, dose escalation and expansion
      study of AO-176 in patients with solid tumors. Part A of this study will examine escalating
      repeat doses of AO-176 monotherapy in patients with select advanced solid tumors (epithelial
      ovarian carcinoma, including primary peritoneal and fallopian tube carcinoma, squamous cell
      carcinoma of head and neck, endometrial carcinoma, castration resistant prostate cancer,
      non-small cell lung adenocarcinoma, papillary thyroid carcinoma, pleural or peritoneal
      malignant mesothelioma and gastroesophageal adenocarcinoma) for which standard therapy proven
      to provide clinical benefit does not exist or is no longer effective.

      The study utilizes a classic 3+3 design, with enrollment of 3 patients per cohort and
      expansion of the cohort in the event of a dose-limiting toxicity (DLT).

      Once the maximum-tolerated dose (MTD)/recommended phase 2 dose (RP2D) has been established,
      tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate
      preliminary efficacy of AO-176.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; the cohort will be expanded in the event of a DLT.
Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of AO-176 assessed by adverse events and laboratory abnormalities</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AO-176 Anti-Tumor Activity assessed by changes in response criteria</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Evaluate objective response rate of AO-176 using RECIST v1.1 and iRECIST.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>AO-176 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AO-176 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AO-176</intervention_name>
    <description>Humanized monoclonal antibody (mAb) targeting CD47</description>
    <arm_group_label>AO-176 Dose Escalation</arm_group_label>
    <arm_group_label>AO-176 Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria

          1. Select advanced solid tumor for which standard therapy proven to provide clinical
             benefit does not exist, or is no longer effective

          2. Measurable disease

          3. ECOG status 0-1

          4. Resolution of prior-therapy-related adverse effects

          5. Minimum of 3 weeks or 5 half-lives since last dose of cancer therapy

        Key Exclusion Criteria:

          1. Previous hypersensitivity reaction to treatment with another monoclonal antibody

          2. Prior treatment with a checkpoint inhibitor (anti-PD-1, PD-L1, CTLA-4 etc.) within 4
             weeks

          3. Prior treatment with a CD47-targeted therapy

          4. Prior organ or stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jackie Walling, MBChB, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Arch Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Romanko, DPM</last_name>
    <phone>4156714028</phone>
    <email>kromanko@archoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Douglas</last_name>
    <email>adouglas@archoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiomara Menendez, RN,BSN</last_name>
      <email>menendez_x@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lorraine Martinez</last_name>
      <email>Lorraine.Martinez@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Anthony El-Khoueriy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Hooker</last_name>
      <phone>415-353-7084</phone>
      <email>Claire.Hooker@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Pamela Munster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215-5450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christin Whalen, RN, BSN, OCN</last_name>
      <email>christin_whalen@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Joyce Liu, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-339-4214</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Phillips, RN, BSN, OCN, CCRP</last_name>
      <email>claudia.phillips@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alex Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.archoncology.com</url>
    <description>Arch Oncology website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>February 4, 2019</study_first_submitted>
  <study_first_submitted_qc>February 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD47</keyword>
  <keyword>AO-176</keyword>
  <keyword>Immunotherapy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

